Epilepsy in the elderly

Seminars in Neurology

Volumn 28, Issue 3, 2008, Pages 336-341

  Jetter, Gina Mapes ^a   Cavazos, Jose E ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Geriatrics

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMOTRIGINE; LEVODOPA; NEUROLEPTIC AGENT; NIMODIPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SIMVASTATIN; STEROID; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VITAMIN D; WARFARIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; ATAXIA; BEHAVIOR CHANGE; BRAIN DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; COMPLEX PARTIAL SEIZURE; CONFUSION; DEMENTIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ELECTROENCEPHALOGRAM; EPILEPSY; FOCAL EPILEPSY; FOOD DRUG INTERACTION; FOOT EDEMA; GINGIVA HYPERTROPHY; HEAD INJURY; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; INSOMNIA; MEMORY DISORDER; MENTAL HEALTH; METABOLIC ENCEPHALOPATHY; MONOTHERAPY; MYOCLONUS; NEPHROLITHIASIS; PRIORITY JOURNAL; PSEUDODEMENTIA; RASH; RECURRENT DISEASE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TREMOR; WEIGHT GAIN;

AGED; AGING; ANTICONVULSANTS; DIAGNOSTIC ERRORS; DRUG INTERACTIONS; EPILEPSY; EPILEPSY, COMPLEX PARTIAL; HUMANS; METABOLIC CLEARANCE RATE;

EID: 49149097901     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1079338     Document Type: Review

References (41)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935-1984. Epilepsia 1993;34:453-458
2. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62:S24-S29
3. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-87
4. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci 2000;55:M384-M392
5. Wallace H, Shorvan S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352:1970-1973
6. Brodie MJ, Kwan P. Epilepsy in elderly people. BMJ 2005;331:1317-1322
7. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine and carbamazepine. Neurology 2005;64:1868-1873
8. So EL, Annegers JF, Hauser WA, O'Brien PC, Whisnant JP. Population-based study of seizure disorders after cerebral infarction. Neurology 1996;46:350-355
9. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in managing epilepsy in the elderly patient. Clin Geriatr 2001; 9:47-56
10. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004;63:S40-S48
11. Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006; 68(suppl 1):S39-S48
12. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029-1035
13. Garnett LK, Morton LD, Waterhouse EJ, et al. Bouncing back after status epilepticus: factors affecting functional outcome [abstract]. Epilepsia 2002;43(suppl):282-283
14. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998;339:792-798
15. Walker MC. Diagnosis and treatment for nonconvulsive status epilepticus. CNS Drugs 2001;15:931-939
16. Treiman DM, Walker MC. Treatment of seizure emergencies: convulsive and non-convulsive status epilepticus. Epilepsy Res 2006;68(suppl 1):S77-S82
17. Litt B, Wityk RJ, Hertz SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998;39: 1194-1202
18. Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003;61:1066-1073
19. Firth M, Prather CM. Gastrointestinal motility problems in the elderly patient. Gastroenterology 2002;122:1688-1700
20. Gidal BE. Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drug. Epilepsy Res 2006; 68(suppl 1):S65-S69
21. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003;60:555-559
22. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38:843-853
23. Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359-373
24. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-304
25. Hudson SA, Farquhar DL, Thompson D, Smith RG. Phenytoin dosage individualization: five methods compared in the elderly. J Clin Pharm Ther 1990;15:25-34
26. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;31:47-64
27. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res 2006;68(suppl 1):S49-S63
28. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999;45: 243-253
29. Willmore LJ. The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 1995;36(suppl 5):S14-S21
30. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151
31. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-771
32. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94
33. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-1116
34. Hoikka V, Alhava EM, Karjalainen P, et al. Carbamazepine and bone mineral metabolism. Acta Neurol Scand 1984;70: 77-80
35. Jetter GM, Moreno L, Rogers S, et al. Changes in vitamin D levels associated with enzyme-inducing AEDs in male epilepsy patients. Epilepsia 2006;47(suppl 4):8
36. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47:510-515
37. Farhat G, Yamount B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353
38. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-257
39. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449
40. Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59:879-882
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22